| Good morning, 360! | Lots of action this week — wowza! Put your two cents in today in the Market Master's Chat Room. Friends don't let friends trade alone! | | FOCUS LIST🔎 | AKAN - Up over 140% in the pre-market after completing reverse-split yesterday | MRUS - Up over 18% in pre after publication of abstracts for its presentation at the 2024 ASCO® annual meeting | GH - Up over 11% in pre after FDA Advisory Committee Panel strongly recommends approval of Shield™ blood test for Colorectal Cancer screening as a primary non-invasive screening option | | *together with Advantage Gold | DEATH 💀F THE D😵LLAR!?! | Must Watch: EXPLOSIVE Documentary on How to Protect Your Hard Earned Money from the Next Wave of Inflation & Money Printing | | (You can't watch this on Youtube, X, Facebook, Truth, or Rumble!) | Secure Your Exclusive Access to Advantage Gold's Inflation Survival Kit |
|
| | HOTLIST🔥 | AKAN - Up over 140% in the pre-market after completing reverse-split yesterday | Akanda Corp. (AKAN) through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. | The company completed a 1-for-40 reverse stock split yesterday reducing the amount of shares outstanding. This has reduced the number of shares from around 80 million to just above 2 million. | After significant weakness and selling pressure due to capital raising, the stock has traded up over 140% in the pre-market this morning after completing the reverse split. | | The $4.80 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $5.50, $6 and then the pre-market high at $6.50. Beyond that, $7.50, $10 and $12 come into play. | Below $4.80, targets to the downside are $4.40, $4, $3.50 and then a gap to fill at $2.39. | | MRUS - Up over 18% in pre after publication of abstracts for its presentation at the 2024 ASCO® annual meeting | Merus N.V. (MRUS) is a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. | In the after hours yesterday, the company released abstracts for its presentation at the 2024 ASCO® annual meeting. The company plans on presenting: | MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT | MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT | Bill Lundberg, M.D., President, Chief Executive Officer of Merus stated: | "MCLA-129 continues to show strong monotherapy activity in EGFR mutant non-small cell lung cancer, and MCLA-145 is now the fourth molecule based on our technology to demonstrate clinical activity. We are looking forward to providing additional detail at 2024 ASCO®." | The stock traded up over 18% in the pre-market in reaction to the results and in anticipation of further data. | | The $52 area was resistance in the after-hours and now becomes a potential support level. | Above it, the first target for bulls is the pre-market high at $54.24. Beyond that is all time highs and blue sky. Round numbers such as $55 and $60 are potential targets. | Below $52, targets to the downside are $50, $48, $46 and then a gap fill $44.07. | |
Watch This Replay 👀
|  | *Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| Can Jason do this with penny stocks?
Swing for the fences with…
Jason Bond Picks & take the challenge with him! | Right Now $297/Quarter! |
|
| | GH - Up over 11% in pre after FDA Advisory Committee Panel strongly recommends approval of Shield™ blood test for Colorectal Cancer screening as a primary non-invasive screening option | Guardant Health, Inc. (GH) is a precision oncology company that provides blood and tissue tests, data sets, and analytics in the United States and internationally. | In the pre-market this morning, the company announced that the FDA Advisory Committee Panel strongly recommends approval of Shield™ blood test for Colorectal Cancer screening as a primary non-invasive screening option | The advisory committee offers valuable non-binding recommendations for the FDA. | The blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests | Shield remains on track to become the first FDA-approved blood test that meets performance requirements for Medicare coverage. | The stock traded up over 11% in the pre-market in reaction to the news. | | The $24.15 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $25, $26, $27, $28 and then the per-market high at $28.39. Beyond that, $29 and $30 come into play. | Below $24.15, there is a gap to fill at $22.51. | | MARKET NEWS 📰 | | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers mentioned in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. |
|
|
|
Post a Comment
Post a Comment